The Toronto Stock Exchange reports that Aptose Biosciences Inc. will be delisted at the close on July 3, 2026. According to the TSX, HS North America Ltd., a wholly owned subsidiary of Hanmi Pharmaceutical Co. Ltd., acquired all of the outstanding common shares of Aptose for $2.41 in cash per share pursuant to a plan of arrangement.

To receive the consideration, shareholders must return the letter of transmittal together with share certificates to Computershare Investor Services Inc. at its principal offices in Toronto.

For more information, see Aptose's management information circular dated Feb. 23, 2026, available on SEDAR+.